RobertL.ColemanMD

Obstetrics & Gynecology • The Woodlands, TX

Gynecologic Oncology

Chief Scientific Officer, US Oncology Research

Join to view full profile

Dr. Coleman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Coleman's full profile

Already have an account?

Office
10101 Woodloch Forest Dr
The Woodlands, TX 77380
Phone+1 281-974-8961

Education & Training

Creighton UniversityB.S., Mathematics, 1983
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1991 - 1993
McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 1987 - 1991
Creighton University School of MedicineClass of 1987

Certifications & Licensure

TX State Medical License 1992 - 2025
IA State Medical License 1994 - 1999
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Giants of Cancer Care MJH Life Sciences, 2020
APGO CREOG Excellence in Teaching APGO CREOG, 2019
Margaret Greenfield/Carmel Cohen, MD, Excellence in Ovarian Cancer Research P Gynecologic Cancer Foundation, 2011
Faculty Development Award APGO/CREOG, 1999
APGO Excellence in Teaching Award APGO Medical Education Foundation, 1994
Junior Faculty Development Award Berlex Foundation, 1994
Clinical Oncology Fellowship Award American Cancer Society, 1992
Outstanding Resident Award Chicago Maternity Center, 1991
Reis Resident Research Award Northwestern University, 1991
Medical Foundation Scholarship Creighton University, 1986
Alpha Omega Alpha (AOA) 1986
Alpha Omega Alpha Medical Research Forum, First Place 1985
Alpha Omega Alpha Medical Research Forum, Third Place 1984
Pi Mu Epsilon 1982
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer Start of enrollment: 2003 Aug 01
Unknown status
Phase 3
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Start of enrollment: 2006 Nov 01
Terminated
Phase 1
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Start of enrollment: 2006 Dec 19
Terminated
Phase 2
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Start of enrollment: 2006 Mar 01
Terminated
Not Applicable
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer Start of enrollment: 2010 Apr 30
Active, not recruiting
Phase 2
Neoadjuvant Therapy for Ovarian Cancer Start of enrollment: 2010 May 17
Completed
Phase 2
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Start of enrollment: 2011 Sep 20
Completed
Phase 1
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Apr 09
Completed
Phase 2
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2015 Jul 01
Recruiting
Phase 1
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Start of enrollment: 2013 Aug 05
Terminated
Phase 1
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Start of enrollment: 2014 Mar 27
Active, not recruiting
Phase 3
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Start of enrollment: 2013 Nov 30
Completed
Phase 1, Phase 2
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2015 Apr 01
Completed
Phase 2
UltraShape Device for Thigh Fat and Circumference Reduction vs. Control Start of enrollment: 2015 Jun 01
Unknown status
Not Applicable
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

264 citations
Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer
Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher
Journal of Clinical Oncology. 2019-06-19
559 citations
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert Hurwitz, Alan Sandler, David Miles, Robert L. Coleman
Cancer Treatment Reviews. 2020-06-01
109 citations
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
Ignace Vergote, Christian Marth, Robert L. Coleman
Cancer Metastasis Reviews. 2015-01-07

Journal Articles

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer
Shannon N Westin, Lois M Ramondetta, Kathleen M Schmeler, Pamela T Soliman, Nicole D Fleming, Jennifer K Burzawa, Alpa M Nick, Andrea M Milbourne, Diane C Bodurka, Rob..., American Journal of Obstetrics and Gynecology
Demcizumab Combined with Paclitaxel for Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: The SIERRA Open-Label Phase Ib Trial
Robert Coleman, MD, Gynecologic Oncology
Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer
Pedro T Ramirez, Robert L Coleman, Michael Frumovitz, The New England Journal of Medicine
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK, Clin Cancer Res, 1/1/2015
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK, Cancer Metastasis Rev, 1/1/2015
Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
Previs RA, Coleman RL, Harris AL, Sood AK, Clin Cancer Res, 1/1/2015
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL, J Clin Oncol, 1/1/2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or prima...
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM, Gynecol Oncol, 1/1/2015
Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK, Gynecol Oncol, 1/1/2014
Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib
Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Je..., Clin Cancer Res, 1/1/2014
Utility of (18)F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary
Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT, Gynecol Oncol, 1/1/2014
Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, L..., Clin Cancer Res, 1/1/2014
The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH, Int J Gynecol Cancer, 1/1/2014
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer
Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, B..., Clin Cancer Res, 1/1/2014
Notch3 Pathway Alterations in Ovarian Cancer
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM..., Cancer Res, 1/1/2014
Randomized phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian t...
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M, Eur J Cancer, 1/1/2014
Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Bereste..., Cancer Biol Ther, 1/1/2014
Banking placental tissue: an optimized collection procedure for genome-wide analysis of nucleic acids
Wolfe LM, Thiagarajan RD, Boscolo F, Tache V, Coleman RL, Kim J, Kwan WK, Loring JF, Parast M, Laurent LC, Gynecol Oncol, 1/1/2014
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD, Gynecol Oncol, 1/1/2013
Special Feature: Quality of Care in Ovarian Cancer
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
"Off-target" Effects? The Role of Statins in Cancer Biology: Commentary on "Statin use and reduced cancer related mortality Nielsen SF, et al N Engl J med 2012; 367:17...
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
Laparoscopy vs Laparotomy in Early Uterine Cancer: We Still Don't Know: Commentary on "Recurrence and survival after random assignment to laparoscopy versus laparotomy...
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
The Right Care, the Right Time, the Right Doc: Only Part of The StoryCommentary on "Disparities in ovarian cancer care quality and survival according to race and socio...
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
Targeted Therapy for LGSOC Shows Promise, Commentary on: "Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, sin...
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
PAP 30-The Next Generation, Commentary on: "Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers Kinde I, et al Sco Transl Med 2013; ...
Coleman RL, OB/GYN Clinical Alert, 1/1/2013
Join now to see all

Books/Book Chapters

60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center
Chapter: Ovarian Cancer
Coleman RL, Gershenson DMEditors: MA Rodriquez, RS Walters, TW Burke.Springer, New York, NY2013
Gynecologic Oncology
Chapter: Targeted Therapy and Immunotherapy
Coleman R, Sabbatini P2012
An Atlas of Gynecologic Oncology: Investigation and Surgery
J. Richard Smith, Giuseppe del Priore, Robert L. Coleman, John MonaghanInforma HealthcareEdition 3rd,2011
Textbook of Gynaecological Oncology
Chapter: Novel Biologic and Cytotoxic Chemotherapies in Epithelial Ovarian Cancer
Moroney, John W and Coleman, Robert LEditors: Ali Ayhan, Nicholas Reed, Murat Gultekin, Polat Dursun.Gunes Publishing, Turkey2011
The Tumor Microenvironment
Chapter: Role of pericytes in resistance to antiangiogenic therapy
Page 311 - 324Matsuo K, Lu C, Shahzad MMK, Coleman RL, Sood AKEditors: RG Bagley.Springer, New York, NY2010
Chapter: Novel Biologic and Cytotoxic Chemotherapeutics in Epithelial Ovarian Cancer
Page 359 - 367Coleman RL, Moroney JWGunes Publishing, Ankara, Turkey2009
Ovarian Cancer: State of the Art, 1
Chapter: Molecular therapeutics in epithelial ovarian cancer
Page 109 - 160Alpa M. Nick, Robert L. Coleman, and Anil K. SoodEditors: Robert C. Bast, Jr. and Maurie Markman.Remedica, London, UK2009
Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy
Chapter: Laparoscopic Sentinel Lymph Node Identification in Cervical Cancer
Page 447 - 452Ramirez PT, Levenback C, Coleman RLEditors: Camran Nezhat, Farr Nezhat, Ceana Nezhat.Cambridge University Press, New York, NYEdition 3rd,2008
Gynecologic Procedures for the General Surgeon, Operative Techniques in General Surgery. 9, Issue 2
Chapter: Ovarian Cancer Staging
Page 51 - 91Han LY, Coleman RLEditors: Koltun WA.Elsevier, Philadelphia, PA2007
Laparoscopic Surgery: Principles and Procedures
Chapter: Gynecology
Herzog TJ, Kost ER, Coleman RLMarcel Dekker, Inc.2004
Gynecology & Obstetrics
Chapter: Radiotherapy in vulvar carcinoma
Coleman RL, Coleman FKJB Lippincott2004
Surgery for Ovarian Cancer: Principles and Practice
Chapter: Secondary cytoreductive surgery
Coleman RL, Munkarah A, Bristow REParthenon Publishing Group Limited2004
Gynecology & Obstetrics
Chapter: Fallopian tube cancer
Rao GG Coleman RLJB Lippincott2004
Principles and Practice
Chapter: Secondary cytoreduction surgery for ovarian cancer
Coleman RLParthenon Publishing2003
Atlas of Gynecologic Oncology
Chapter: Lymphatic mapping
Coleman RLTaylor & Francis Books, Ltd2003
Atlas of Clinical Oncology
Chapter: Anatomy and natural history of invasive female lower genital tract cancers (FLGTCs): Carcinomas of the cervix, vagina, and vulva.
Page 47 - 62Coleman RLB.C. Decker Inc.2001
Handbook of Gyn Oncology
Santoso JT, Coleman RLMcGraw-Hill2001
CLinical Lymphatic Mapping in Gynecologic Cancers
Chapter: Clinical Lymphatic Mapping in Gynecologic Cancers
Levenback C, Coleman R, Van der Zee AGJMartin Dunitz Ltd2001
Current Treatment Options in Oncology
Chapter: Vulvar carcinoma
Page 177 - 190Coleman RL Santoso JTCurrent Science, Inc.2000
Gynecology & Obstetrics
Chapter: Radiotherapy in epithelial ovarian cancer
Page 1 - 15Coleman RL Coleman FKWilliams & Wilkins/JB Lippincott1999
Gynecology & Obstetrics
Chapter: Fallopian tube carcinoma
Page 1 - 90Coleman RLJB Lippincott1998
Anderson Surgical Oncology Handbook
Chapter: Gynecologic oncology
Page 326 - 368Hallum AV, Coleman RL, Wolf JLittle, Brown and Co1995
Management of Complications in Gynecologic Surgery
Chapter: The retroperitoneal mas
Page 115 - 126Coleman RLWB Saunders Company1995
Study Guide for Textbook of Gynecology
Chapter: Epithelial ovarian cancer
Hallum AV, Coleman RL, Segreti EWB Saunders Company1994
Join now to see all

Abstracts/Posters

Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube...
Coleman RL, Moon J, Sood AK, Delmore JE, Bonebrake AJ, Anderson GL, Alberts DS, Markman M, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2012
A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ...
R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, E. Nowara, L. Gilbert..., 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galbincea, T. A. Johnston, M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman, D. M. Ge..., 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
A phase II evaluation of nab-paclitaxel (Abraxane) in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer...
Coleman RL, Brady B, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS, 2010 ASCO Annual Meeting, 1/1/2010
Association of Body Mass Index and Time under Anesthesia with Laparoscopic Surgical Complications.
S. Uppal, M. Frumovitz, R. dos Reis, A.M. Nick, R.L. Coleman, P.T. Soliman, K.M. Schmeler, P.T. Ramirez, 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL, 1/1/2010
Impact of Surgeon Volume on Patient Outcome in Gynecologic Laparoscopy.
M.J. Worley, C. Anwandter, C.C. Sun, R. Dos Reis, A.M. Nick, M. Frumovitz, R.L. Coleman, P.T. Soliman, K.M. Schmeler, P.T. Ramirez, 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL, 1/1/2010
Rate of Para-Aortic Lymph Node Micrometastasis in Patients with Locally Advanced Cervical Cancer.
B. Zand, E.D. Euscher, P.T. Soliman, K.M. Schmeler, R.L. Coleman, A. Jhingran, M. Frumovitz, L.M. Ramondetta, P.T. Ramirez, 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL, 1/1/2010
SGO White Paper on ovarian cancer: etiology, screening and surveillance
Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ (Introductory Paragraph - Herzog/Coleman), Gynecol Oncol, 1/1/2010
Join now to see all

Lectures

Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and ...
2019 ASCO Annual Meeting - 6/1/2019
Unraveling the Risks and Benefits of Antiangiogenic Therapy for Ovarian Cancer Patients
UPMC Cancer Center, Pittsburgh, PA, 2015; Hackensack University Medical Center, Hackensack, NJ, 2015 - 1/24/2015
Session I: Statistical Design, FDA Drug Approval Procedures; FDA
Salt Lake City, UT - 1/20/2015
Session I: Statistical Design, FDA Drug Approval Procedures
Salt Lake City, UT - 1/19/2015
Pros and Cons; First Relapsed Ovarian Cancer
Berlin, Germany - 1/17/2015
Emerging New Therapies and Predictive Biomarkers
Lahore, Pakistan - 1/14/2015
Interactive Cases
Lahore, Pakistan - 1/14/2015
Role of Lymphadenectomy in Endometrial Cancer
Lahore, Pakistan - 1/14/2015
Advances in the Management of Cervical and Endometrial Carcinoma
Las Vegas, NV - 1/14/2015
Clinical Experience with PARP in Ovarian Cancer and the New Path to Regulatory Approval
Basser Research Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA - 1/11/2015
Ovarian Cancer
Multiple Locations, 1994, 1997, 1999, 2014, 2015 - 1/4/2015
Bevacizumab Debate: Platinum Sensitive vs Platinum Resistant
Houston, TX - 1/1/2015
Selecting the Best Therapy for Recurrent Ovarian Cancer: Progress in Response Prediction over the Last 50 Years
Chicago, IL - 1/31/2014
Ovarian Cancer: Standards of Care and New Opportunities
Chicago, IL - 1/29/2014
Novel Targeted Agents and Angiogenesis Inhibitors for Ovarian Cancer
Las Vegas, NV - 1/28/2014
Gynecologic Cancer
Panama City, Panama - 1/26/2014
Clinical Trials and New Treatments
West Palm Beach, FL - 1/25/2014
Scientific Plenary VII: Ovarian Cancer Clinical Trials: Endpoint Validation and "Practice Changing" Results
Tampa, FL - 1/25/2014
Ovarian Cancer Treatment Updates
Wake Forest School of Medicine, Greensboro, NC - 1/25/2014
Education Forum VI: Tumor Board
Tampa, FL - 1/24/2014
Modern Approach to Genetic Testing and Management of BRCA1/2 Mutation Carriers
Duke University, Department of Gynecologic Oncology, Durham, NC - 1/21/2014
Future Clinical Trial Designs and Biomarkers for Anti-Angiogenic Therapy
Madrid, Spain - 1/20/2014
The ovarian cancer "Moonshot". A translational research perspective.
Madrid, Spain - 1/19/2014
Ask The Experts
Washington, DC - 1/13/2014
Role of Anti-Angiogenic Therapy in Ovarian Cancer
Medellin, Colombia - 1/11/2014
Join now to see all

Other

Ovarian Cancer Update: Conversations with Oncology Investigators (Faculty Interview)
Coleman RL, Research to Practice
Miami, FL - 1/1/2011
Ovarian Cancer: Answers to the 10 Most Important Questions
Coleman RL, Hosted by CancerNet Japan. Sponsored by GOTIC (Gynecologic Oncology Trial and Investigation Consorti
1/9/2010
Recurrent Ovarian Cancer: State of the State
Coleman RL, Living Medical Textbook from Projects in Knowledge CME Activity - Oncology Women's Cancers Edition,
Little Falls, NJ - 1/19/2009
Clinical Trials and Future Treatments
Coleman RL, The Ovarian Cancer Support Group, The University of Texas M. D. Anderson Cancer Center
Houston, TX - 1/9/2009
Virtual Ovarian Tumor Board
Coleman RL, Live CME Program, sponsored by Postgraduate Institute for Medicine and IMPACt Inc.
1/24/2008
Looking Ahead: Emerging Options in Treatment of Ovarian Cancer.
Coleman RL, Expert Panel Discussions
1/6/2008
Current Therapeutic Options and Clinical Issues in Recurrent Ovarian Cancer: Where Do We Stand?
Coleman RL, Expert Panel Discussions
1/6/2008
Recognizing and Overcoming Challenges in the Treatment of Recurrent Ovarian Cancer
Coleman RL, Expert Panel Discussions
1/6/2008
Ovarian Cancer Update: Conversations with Oncology Investigators, Bridging the Gap between Research and Patient Care.
Coleman RL, Research To Practice
Miami, FL - 1/1/2008
Advances in the Treatment of Gynecologic Cancer
Coleman RL, M.D. Anderson Patient Power live web cast
1/21/2007
Ovarian Cancer Telephone Workshop
Coleman RL, The Gynecologic Cancer Foundation
1/19/2007
New approaches to ovarian cancer therapy. (Interview)
Coleman RL, CURE's Winter Issue
1/1/2007
Ovarian and Cervical Cancer: Emerging Therapeutic Paradigms
Coleman RL, Herzog TJ, Continuing Edge: USA
1/1/2007
CA-125 and Its Role in the Management of Ovarian Cancer
Coleman RL, The Ovarian Cancer Support Group, The University of Texas M. D. Anderson Cancer Center
M. D. Anderson Cancer Center - 1/13/2006
Current Trends in the Treatment of Ovarian Cancer
Coleman RL, CME Monograph
1/1/2006
Breakthroughs in Ovarian Cancer 2005
Coleman RL, The Ovarian Cancer Support Group, The University of Texas M. D. Anderson Cancer Center
M. D. Anderson Cancer Center - 1/8/2005
GCF Telephone Education Workshop on Clinical Trials for Recurrent Ovarian Cancer Phase III and IV
Coleman RL
1/1/2005
Platinum Compounds in the Treatment of Ovarian Cancer
Coleman RL
1/1/2005
Patterns of Practice in Selected Gynecologic Malignancies
Coleman RL
1/1/2005
Cases in Advanced Gynecologic Cancers: A Virtual Tumor Board Discussion
Coleman RL
1/1/2005
Alvimopan Postoperative Ileus (POI) Development Program
Coleman RL
Philadelphia, PA - 1/21/2004
Clinical Insights
Coleman RL, CME CD
1/1/2004
Bowel Surgery Monograph
Coleman RL
1/1/2000
Ovarian Cancer Monograph
Coleman RL
1/1/2000
Ovarian & Cervical Cancer Monograph
Coleman RL
1/1/2000
Join now to see all

Authored Content

SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 2023
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020

Press Mentions

SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 25th, 2023
Maintenance Therapy the 'Biggest Breakthrough in Decades' for Ovarian CancerSeptember 15th, 2022
Health Care Giants McKesson and HCA Partner up in Cancer Research Joint VentureJune 23rd, 2022
Join now to see all

Grant Support

Uterine SPORE Project 3NCI2004–2016
Ovarian SPORE - Project 2NCI2004–2016
EpharnaCPRIT2011–2015

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member